Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and quality of life in women with
advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the
breast), HR+ / HER2-, who are treated with an aromatase inhibitor or fulvestrant as baseline
therapy in combination with palbociclib (Ibrance)